Deferiprone iron chelation as a novel therapy for experimental mucormycosis
نویسندگان
چکیده
منابع مشابه
Role of deferiprone in chelation therapy for transfusional iron overload.
Before 1987, iron chelation therapy for patients with thalassemia major and other refractory anemias requiring regular transfusions depended almost entirely on one drug, deferoxamine. The drug has dramatically increased survival in patients with thalassemia major in countries where it is readily available.1,2 Although many other compounds had been tried as iron-chelating agents in experiments w...
متن کاملIron chelation as a potential therapy for neurodegenerative disease.
Neurodegenerative disorders include a variety of pathological conditions, which share similar critical metabolic processes such as protein aggregation and oxidative stress, both of which are associated with the involvement of metal ions. Chelation therapy could provide a valuable therapeutic approach to such disease states, since metals, particularly iron, are realistic pharmacological targets ...
متن کاملSafety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes...
متن کاملOral iron chelation therapy with deferiprone in patients with Thalassemia Major.
OBJECTIVE To determine the efficacy and adverse effects of deferiprone in patients with Thalassemia Major. METHODS A prospective case series study was conducted at the Fatimid Foundation Blood Bank and Haematological Diseases center Lahore. A total of 87 patients entered into the study between September 2005 and November 2006. Deferiprone was given at subsidized rates at a dose of 75/mg/day f...
متن کاملCombined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
Dear Editor-in-Chief, We shortly report our results of combined iron chelation therapy with deferiprone (DFP) and desferrioxamine (DFX) versus chelation therapy with DFP alone, in iron overloaded β-thalassemia patients. Desferrioxamine has been a life saving iron chelator for thousands of patients in the last 40 years. However, less than 10% of the patients requiring iron chelation therapy worl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Antimicrobial Chemotherapy
سال: 2006
ISSN: 0305-7453,1460-2091
DOI: 10.1093/jac/dkl350